Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.41 Increased by +30.51% | -0.28 Decreased by -47.16% |
| Nov 7, 24 | -0.27 Increased by +40.00% | -0.28 Increased by +3.57% |
| Aug 13, 24 | -0.26 Increased by +65.79% | -0.33 Increased by +21.21% |
| May 8, 24 | -1.14 Decreased by -119.23% | -0.53 Decreased by -115.09% |
| Feb 28, 24 | -0.59 Decreased by -268.75% | -0.46 Decreased by -28.26% |
| Nov 2, 23 | -0.45 Increased by +19.64% | -0.67 Increased by +32.84% |
| Aug 3, 23 | -0.76 Decreased by -26.67% | -0.54 Decreased by -40.74% |
| May 4, 23 | -0.52 Increased by +13.33% | -0.42 Decreased by -23.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -34.74 M Decreased by -45.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -13.68 M Increased by +23.65% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.85 M Increased by +79.90% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -54.40 M Decreased by -97.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 4.84 M Increased by +N/A% | -23.86 M Decreased by -682.90% | Decreased by -493.26% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -17.92 M Decreased by -12.11% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -29.13 M Decreased by -71.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -27.48 M Decreased by -48.74% | Decreased by N/A% Decreased by N/A% |